 LONDON, April 20, 2021 GLOBE NEWSWIRE -- Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway ILAP designation from the UK Medicines and Healthcare products Regulatory Agency MHRA for AUTO4 being studied in a Phase 1 study in TRBC1 positive Peripheral T Cell Lymphoma PTCL. 